ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1173

Prevalence of Coronary Artery Involvement in IgG4-Related Disease Detected by Non-Gated Cross-Sectional Imaging
Abstract Number: 1174

High Prevalence of Autoimmunity in Rosai Dorfman Disease: A Multinational Study
Abstract Number: 1175

Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study
Abstract Number: 1176

VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation
Abstract Number: 1177

Pregnancy Outcomes in Women with Familial Mediterranean Fever Treated with Anakinra: A Retrospective Study
Abstract Number: 1178

An International modified Delphi Study on the evolving role of Janus kinase inhibitors (JAKi) in rheumatic and musculoskeletal diseases (RMDs)
Abstract Number: 1179

Efficacy and Safety of Ruxolitinib in Adult Patients With Refractory Connective Tissue Disease-Associated Macrophage Activation Syndrome
Abstract Number: 1180

Gender-Based Clinical Differences in Behçet’s Syndrome: Findings from a 24-Year Cohort in a Non-Endemic and Multiethnic Country
Abstract Number: 1181

Clinical Relevance of Tumor Necrosis Factor Superfamily Cytokines
Abstract Number: 1182

Cardiac Sarcoidosis in Black Patients: A Biopsy-Confirmed Cohort Study
Abstract Number: 1183

Risk of Inflammatory Bowel Disease in Psoriatic Arthritis Patients Treated with IL-17 Inhibitors
Abstract Number: 1184

Does Blocking IL-17 Treat Recalcitrant Uveitis? Explorative Study on the Use of Ixekizumab to Manage Patients with Uveitis.
Abstract Number: 1185

Pulmonary Arterial Hypertension in Adults with Still’s Disease: Another Pulmonary Manifestation Associated with HLA-DRB1*15
Abstract Number: 1186

Increased Adoption of IL-1 Pathway Inhibition and the Steroid-sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment From the RESONANCE Patient Registry
Abstract Number: 1187

Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].